{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T06:08:44Z","timestamp":1762409324780,"version":"3.37.3"},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T00:00:00Z","timestamp":1499385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bendamustine (B) associated with rituximab (R) is widely described in literature for the management of patients with chronic lymphoid leukaemia (CLL) and indolent non\u2010Hodgkin lymphoma. Safety data regarding late hematotoxicity such as late onset neutropenia (LON) are scarce. The aim of our study was to assess the incidence and to identify risk factors for LON in patients with indolent non\u2010Hodgkin lymphoma and CLL treated with B and R (B\u2010R).<\/jats:p><jats:p>One hundred forty five patients were treated with B\u2010R as first or second line. Patients with neutropenia prior induction treatment, treated beyond second line and relapsing within 3\u00a0months after the end of induction treatment, were excluded. Patients receiving at least 1 cycle of B\u2010R and having LON during follow\u2010up period were included and considered as eligible for toxicity assessment. A complete blood count was performed 4 weeks after the last cycle of induction treatment and thereafter every 3 months for 1 year.<\/jats:p><jats:p>Thirty six patients were identified in our cohort (incidence of 25%), mostly affected by CLL (n\u00a0=\u00a011) and follicular lymphoma (FL) (n\u00a0=\u00a015). During follow\u2010up, 84 events of LON were recorded, 61% and 39% were of grades 1\/2 and 3\/4, respectively. No episode of febrile neutropenia was documented. Amongst 13 of the 15 patients with FL undergoing R maintenance, 8 had treatment discontinuation because of LON. Median time for LON (grade\u00a0&gt;\u00a02) and time to recovery (grade\u00a0&lt;\u00a03) were of 11.2 and 17.3\u00a0weeks, respectively. One year after B\u2010R induction, LON persisted in 4 patients. The risk of LON was increased both in patients with FL or CLL and performance status &gt;1.<\/jats:p><jats:p>The LON in B\u2010R treated patients is clinically relevant. Close clinical and biological follow\u2010up and treatment prophylaxis (eg, valaciclovir and cotrimoxazole) especially for FL patients undergoing maintenance with R monotherapy seems relevant.<\/jats:p>","DOI":"10.1002\/hon.2458","type":"journal-article","created":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T12:39:52Z","timestamp":1499431192000},"page":"144-149","source":"Crossref","is-referenced-by-count":7,"title":["Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab"],"prefix":"10.1002","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7301-3465","authenticated-orcid":false,"given":"B.","family":"Verriere","sequence":"first","affiliation":[{"name":"Pharmacy department Antibes Hospital  Antibes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Gastaud","sequence":"additional","affiliation":[{"name":"Oncology department Anticancer Center Antoine Lacassagne  Nice France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Chamorey","sequence":"additional","affiliation":[{"name":"Biostatistics and epidemiology department Anticancer Center Antoine Lacassagne  Nice France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Peyrade","sequence":"additional","affiliation":[{"name":"Oncology department Anticancer Center Antoine Lacassagne  Nice France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Deletie","sequence":"additional","affiliation":[{"name":"Pharmacy department Antibes Hospital  Antibes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Bouredji","sequence":"additional","affiliation":[{"name":"Oncology and hemato oncology department Antibes Hospital  Antibes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Quinsat","sequence":"additional","affiliation":[{"name":"Internal Medicine department Antibes Hospital  Antibes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Schiappa","sequence":"additional","affiliation":[{"name":"Biostatistics and epidemiology department Anticancer Center Antoine Lacassagne  Nice France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Thyss","sequence":"additional","affiliation":[{"name":"Oncology department Anticancer Center Antoine Lacassagne  Nice France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Re","sequence":"additional","affiliation":[{"name":"Oncology department Anticancer Center Antoine Lacassagne  Nice France"},{"name":"Oncology and hemato oncology department Antibes Hospital  Antibes France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,7,7]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00447-7"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30051-1"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.389"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.268"},{"key":"e_1_2_6_11_1","unstructured":"European medicines agency\u2014EPAR\u2014MabThera. [http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000165\/human_med_000897.jsp&mid=WC0b01ac058001d124]."},{"key":"e_1_2_6_12_1","unstructured":"Common terminology criteria for adverse events (CTCAE)\u2010 CTCAE_4.03_2010\u201006\u201014_QuickReference_5x7.pdf."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181f2caef"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.679266"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.11.62"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21818"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2011.02587.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000177551.13714.33"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21433"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0274"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04385.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-008-9049-z"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021113"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016725"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.48.1368"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200306263482620"},{"key":"e_1_2_6_27_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2015.07.635","article-title":"Late\u2010onset neutropenia after rituximab\u2010containing therapy for non\u2010Hodgkin lymphoma","author":"Aguiar\u2010Bujanda D","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl393"},{"issue":"4","key":"e_1_2_6_29_1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3747\/co.22.2431","article-title":"An open\u2010label expanded\u2010access trial of bendamustine in patients with rituximab\u2010refractory indolent non\u2010Hodgkin lymphoma or previously untreated chronic lymphocytic leukemia: BEND\u2010ACT","volume":"22","author":"Kouroukis CT","year":"2015","journal-title":"Curr Oncol"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2135-8"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.86"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.009"},{"issue":"2","key":"e_1_2_6_33_1","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.3324\/haematol.11031","article-title":"Late\u2010onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF\u2010induced B\u2010cell recovery","volume":"92","author":"Terrier B","year":"2007","journal-title":"Haematologica"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2727-6"},{"key":"e_1_2_6_35_1","article-title":"Two years rituximab maintenance vs. observation after first\u2010line treatment with bendamustine plus rituximab (B\u2010R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7\u20102008 MAINTAIN trial)","volume":"34","author":"Rummel MJ","year":"2016","journal-title":"J Clin Oncol (ASCO Annual Meeting)"},{"key":"e_1_2_6_36_1","article-title":"Rituximab maintenance for a maximum of 5 years after single\u2010agent rituximab induction in follicular lymphoma: results of the randomized controlled phase III trial SAKK 35\/03","author":"Taverna C","year":"2015","journal-title":"JCO"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2458","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:55:16Z","timestamp":1695552916000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,7]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1002\/hon.2458"],"URL":"https:\/\/doi.org\/10.1002\/hon.2458","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"type":"print","value":"0278-0232"},{"type":"electronic","value":"1099-1069"}],"subject":[],"published":{"date-parts":[[2017,7,7]]}}}